COMMUNIQUÉS West-GlobeNewswire

NEXGEL to Report Second Quarter 2024 Financial Results on August 14th

12/08/2024 - 15:15

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over- [...]

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

12/08/2024 - 15:12

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of [...]

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

12/08/2024 - 15:05

ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab [...]

Health AI Company Akido Establishes Ethics Council on Artificial Intelligence in Healthcare with Caltech’s Merkin Institute and the Keck School of Medicine of USC Department of Surgery

12/08/2024 - 15:05

Akido’s Breakthrough AI Unlocks a Reimagined Care Experience with a Focus on Bringing Exceptional Healthcare to All The Council will Establish Ethical Guidelines for the AI Industry and the Technology’s Integration into [...]

MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application

10/08/2024 - 03:33

MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies ( MAPS [...]

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

10/08/2024 - 00:18

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

09/08/2024 - 23:59

Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye [...]

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

09/08/2024 - 22:40

KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead [...]

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 22:30

CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

09/08/2024 - 22:30

Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Phase [...]

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

09/08/2024 - 22:20

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

09/08/2024 - 22:15

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today [...]

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

09/08/2024 - 22:05

- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds from a May 2024 [...]

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 22:05

BRISBANE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on August 6, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock [...]

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 22:05

MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

09/08/2024 - 22:05

JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial [...]

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

09/08/2024 - 22:05

– 2 nd quarter conference call to be held Tuesday, August 13 th , at 8:30 a.m. ET – DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company [...]

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 22:05

SAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

09/08/2024 - 22:04

Study validates siRNA produced by new GMP-compliant Manufacturer and Company’s Exosomes for Drug Delivery TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) ( [...]